Jaboticaba extract prevents prediabetes and liver steatosis in high-fat-fed aging mice

• Main Authors: C.A. Lamas, S.A. Lenquiste, A.M. Baseggio, L. Cuquetto-Leite, L.A. Kido, A.C. Aguiar, M.N. Erbelin, C.B. Collares-Buzato, M.R. Maróstica, Jr., V.H.A. Cagnon
• Format: Article
• Language: English
• Published: Elsevier 2018-08-01
• Series: Journal of Functional Foods
• Subjects: Bioactive compounds; Jaboticaba; Obesity; Diabetes; Senescence; Functional food
• Online Access: http://www.sciencedirect.com/science/article/pii/S1756464618303013

We developed a patented jaboticaba peel extract (PJE) aiming to investigate PJE dose-dependent effect in liver and metabolism of high-fat-fed aging mice. Male FVB mice were distributed as follows: YG(young; 3-months-old), AG(aged; 11-months-old), HfAG(aged + high-fat diet), JAGI(aged + 2.9gPJE/Kg), JAGII(aged + 5.8gPJE/Kg), HfJAGI(aged + high-fat diet + 2.9gPJE/Kg) and HfJAGII(aged + high-fat diet + 5.8gPJE/Kg). PJE showed a potent antioxidant activity and high bioactive compounds content. Both PJE doses prevented weight gain, dyslipidemia, hyperglycemia, reduced COX-2 level and improved HDL-cholesterol, pIRS-1, and PPARγ levels in high-fat-fed aging mice. Only HfJAGII showed lower TNFα level, insulin resistance, and glucose intolerance relative to HfAG. Taking aging into consideration, PJE prevented dyslipidemia and hyperglycemia, reduced TNFα besides increasing pIRS-1 and PPARγ levels, and restoring the hepatic structure in aged mice. Thus, PJE anti-inflammatory, hypoglycemic and lipid modulation capacity prevented the pre-diabetes and NAFLD in this model, being indicated as potential therapy to prevent hepatic and metabolic disorders associated to obesity, diabetes, and aging.